m475271 has been researched along with Prostatic-Hyperplasia* in 1 studies
1 other study(ies) available for m475271 and Prostatic-Hyperplasia
Article | Year |
---|---|
Smooth muscle contraction and growth of stromal cells in the human prostate are both inhibited by the Src family kinase inhibitors, AZM475271 and PP2.
In benign prostatic hyperplasia, increased prostate smooth muscle tone and prostate volume may contribute alone or together to urethral obstruction and voiding symptoms. Consequently, it is assumed there is a connection between smooth muscle tone and growth in the prostate, but any molecular basis for this is poorly understood. Here, we examined effects of Src family kinase (SFK) inhibitors on prostate contraction and growth of stromal cells.. SFK inhibitors, AZM475271 and PP2, were applied to human prostate tissues to assess effects on smooth muscle contraction, and to cultured stromal (WPMY-1) and c-Src-deficient cells to examine effects on proliferation, actin organization and viability.. SFKs were detected by real time PCR, western blot and immunofluorescence in human prostate tissues, some being located to smooth muscle cells. AZM475271 (10 μM) and PP2 (10 μM) inhibited SFK in prostate tissues and WPMY-1 cells. Both inhibitors reduced α. In human prostate, smooth muscle tone and growth are both controlled by an SFK-dependent process, which may explain their common role in bladder outlet obstruction. Targeting prostate smooth muscle tone and prostate growth simultaneously by a single compound may, in principal, be possible. Topics: Blotting, Western; Cell Proliferation; Dose-Response Relationship, Drug; Humans; Male; Muscle Contraction; Muscle Tonus; Muscle, Smooth; Prostate; Prostatic Hyperplasia; Pyrimidines; Quinazolines; Real-Time Polymerase Chain Reaction; src-Family Kinases; Stromal Cells | 2016 |